A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT)
Risk Adapted Treatment of Unilateral Favorable Histology Wilms Tumors (FHWT)
Children's Oncology Group
1,656 participants
Apr 15, 2025
INTERVENTIONAL
Conditions
Summary
This phase III trial studies using risk factors in determining treatment for children with favorable tissue (histology) Wilms tumors (FHWT). Wilms Tumor is the most common type of kidney cancer in children, and FHWT is the most common subtype. Previous large clinical trials have established treatment plans that are likely to cure most children with FHWT, however some children still have their cancer come back (called relapse) and not all survive. Previous research has identified features of FHWT that are associated with higher or lower risks of relapse. The term "risk" refers to the chance of the cancer coming back after treatment. Using results of tumor histology tests, biology tests, and response to therapy may be able to improve treatment for children with FHWT.
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Undergo bone scan for patients with metastatic sites outside the chest/abdomen/pelvis documented during therapy
Given IV
Undergo CT
Given IV
Given IV
Given IV
Given IV
Given IV
Undergo MRI
Undergo nephrectomy
Undergo observation after nephrectomy
Undergo PET for patients with metastatic sites outside the chest/abdomen/pelvis documented during therapy
Undergo ultrasound
Given IV
Undergo X-ray
Locations(153)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06401330